Benefit-Risk Considerations During Drug Product Development (8of14) REdI 2018
41:00
FDA Regulatory Requirements for Clinical Investigators and Case Examples (9of14) REdI 2018
57:37
Risk Evaluation and Mitigation Strategies (REMS) Compliance Program
1:00:00
Clinical Pharmacology Considerations for Radiolabeled Mass Balance Studies
4:07:45
FDA Clinical Investigator Training Course (CITC) 2024 (Day 3 of 3)
48:50
Advancing Transparency and Regulatory Science Activities on Risk Evaluation and Mitigation Strategy
4:59:26
FDA Clinical Investigator Training Course (CITC) 2024 (Day 2 of 3)
50:02
Cannabis Products and the Potential Impact on Patients
4:38:30